A Phase 2 interventional study of SKY0402 and Bupivacaine HCl in Inguinal Hernia, sponsored by Pacira Pharmaceuticals, Inc. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing bupivacaine in Hernia, Inguinal — 1 open to participants now, 2 under way, none of them phase 3. Bupivacaine · Hernia, Inguinal.
Among the 19 studies testing bupivacaine in Hernia, Inguinal, this one is the 9th largest by enrollment, is the only one that started in 2004, is one of 3 in phase 2, and was the 1st registered.
545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.
Browse Hernia, Inguinal studies →1 of the 19 studies testing bupivacaine in Hernia, Inguinal is open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Ages 18–75
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 90 across 397 interventional studies indexed under Hernia, Inguinal.
Median enrollment 70 across the 19 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Pacira BioSciences, Inc. has 1 study filed under Hernia, Inguinal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing bupivacaine in Hernia, Inguinal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to determine the appropriate dose of SKY0402 for the management of postoperative pain following inguinal hernia repair. This study evaluated the safety, efficacy, and pharmacokinetics of SKY0402 compared with a 100 mg dose of bupivacaine HCl for the treatment of postoperative pain in subjects undergoing inguinal hernia repair. Study drug was administered by surgical wound infiltration at the end of the hernia repair procedure.
SKY0402 was administered in a dose escalating/de-escalating fashion, with a low starting dose in Cohort 1 that was to be increased or decreased in subsequent cohorts based on safety and analgesic effects. The decision to proceed to the next cohort (i.e., increase or decrease the dose) was made by a Cohort Data Review Committee following a review of the data from the previous cohort. Subjects were randomized to receive either SKY0402 or bupivacaine HCl at a ratio of 1:1 in Cohort 1 and at a ratio of 3:1 in subsequent cohorts. The dose of bupivacaine HCl (100 mg) remained constant for all cohorts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
Drug: SKY0402
Low dose, low-mid dose, mid-dose, and high dose
Drug: Bupivacaine HCl
Single dose of SKY0402 administered locally into the surgical wound.
Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
Time to First Use of Supplemental Pain Medication
The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain
Time frame: Through 96 hours postdose
Adverse Events
Safety assessments included monitoring of treatment-emergent adverse events
Time frame: Through 30 days postdose
| Milestone | Bupivacaine HCl | SKY0402 |
|---|---|---|
| Started | 26 | 50 |
| Completed | 26 | 50 |
| Not completed | 0 | 0 |
The primary efficacy endpoint was the time to first use of supplemental pain medication (opioid or non-opioid) postoperatively for surgical wound pain
| hours | Bupivacaine HCl | SKY0402 Low Dose | SKY0402 Low-mid Dose | SKY0402 High-mid Dose | SKY0402 High Dose |
|---|---|---|---|---|---|
| Time to First Use of Supplemental Pain Medication | 4.2 (1.3 to 13.7) | 13.75 (2.1 to 62.7) | 3.9 (0.8 to 7.4) | 5.2 (1.9 to 18.8) | 5.5 (1.4 to 96) |
Safety assessments included monitoring of treatment-emergent adverse events
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupivacaine HCl | — | 0/26 (0%) | 10/26 (38.5%) |
| SKY0402 | — | 2/50 (4%) | 12/50 (24%) |
| Event | Bupivacaine HCl | SKY0402 |
|---|---|---|
| Postoperative hematomaInjury, poisoning and procedural complications | 0/26 | 1/50 |
| Urinary Retention/BPHRenal and urinary disorders | 0/26 | 1/50 |
| Event | Bupivacaine HCl | SKY0402 |
|---|---|---|
| NauseaGastrointestinal disorders | 2/26 | 4/50 |
| Localized oedemaGeneral disorders | 2/26 | 1/50 |
| Wound infectionInfections and infestations | 2/26 | 0/50 |
| Urinary retentionRenal and urinary disorders | 2/26 | 1/50 |
| PyrexiaGeneral disorders | 1/26 | 3/50 |
| Hypertension NOSVascular disorders | 1/26 | 3/50 |
| Age, Categorical(Participants) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 36 | 60 |
| >=65 years | 2 | 14 | 16 |
| Age, Continuous(years) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| Mean | 51.3 ± 12.6 | 55.1 ± 16 | 53.8 ± 14.5 |
| Sex: Female, Male(Participants) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 26 | 50 | 76 |
| Region of Enrollment(participants) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| Belgium | 0 | 8 | 8 |
| Australia | 16 | 26 | 42 |
| United Kingdom | 4 | 12 | 16 |
| Netherlands | 6 | 4 | 10 |
No study locations are listed for this record.
The record gives a start of Dec 2004, a primary completion of Jan 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 6 years 4 months after primary completion. A results delay was requested in Sep 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine